Related Experiment Video
Updated: Jul 4, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro
Mathieu Vinken1, Tatyana Doktorova, Heidrun Ellinger-Ziegelbauer
1Department of Toxicology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium. mvinken@vub.ac.be
Abstract:
Recent changes in the European legislation of chemical-related substances have forced the scientific community to speed up the search for alternative methods that could partly or fully replace animal experimentation. The Sixth Framework Program project carcinoGENOMICS was specifically raised to develop omics-based in vitro screens for testing the carcinogenic potential of chemical compounds in a pan-European context. This paper provides an in-depth analysis of the complexity of choosing suitable reference compounds used for creating and fine-tuning the in vitro carcinogenicity assays. First, a number of solid criteria for the selection of the model compounds are defined. Secondly, the strategy followed, including resources consulted, is described and the selected compounds are briefly illustrated. Finally, limitations and problems encountered during the selection procedure are discussed. Since selecting an appropriate set of chemicals is a frequent impediment in the early stages of similar research projects, the information provided in this paper might be extremely valuable.
Related Concept Videos
Mutagenicity and Carcinogenicity
In vitro Mutagenesis
In-vitro Mutagenesis
Pharmacogenomics: Identification of New Drug Targets
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

